AzTrials
AzTrials

Faculty of MedicineIrritablebowelNCT06097598

Prevalence of Irritable Bowel Syndrome in Medical Students Africa

An observational study of Faculty of Medicine, run by Assiut University.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The aim of the present study was to assess the prevalence of IBS among medical students in the Middle East and North Africa and to investigate the sociodemographic, lifestyle, and clinical factors associated with IBS. Read more about this study

Who is it for?
Ages Up to 27 yearsHealthy volunteers can take part
Conditions the study is for
Faculty of Medicine
How many people
1,131 participants
Where
No sites listed yet
Study dates
20 Oct 2023to 10 Oct 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 27 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult

Study population: Medical students enrolled in from medical schools located in the Middle East and North Africa.

Who may be able to join

  • Medical students enrolled in from medical schools located in the Middle East and North Africa.

Who cannot join

  • 1- History of significant comorbidities 2- Participants with definite or suspected history of inflammatory bowel disease, celiac disease, Lactose intolerance or peptic ulcer disease. 3- Psychiatric patients or patients on antidepressant treatment or using psychotropic drugs affecting their cognitive ability.

About this study

Official title: Prevalence of Irritable Bowel Syndrome in Medical Students in the Middle East and North Africa

The aim of the present study was to assess the prevalence of IBS among medical students in the Middle East and North Africa and to investigate the sociodemographic, lifestyle, and clinical factors associated with IBS. A better understanding of IBS correlates is expected to improve our therapeutic approach to IBS in this population.

Read the detailed description

Irritable bowel syndrome (IBS) is a multifactorial chronic disease characterized with functional gastrointestinal disorder which affects the quality of life of the patient. Until now the pathophysiology of IBS was not completely understood but it has been related to multiple mechanisms like: visceral hypersensitivity, Brain-gut axis, post infectious inflammation and genetic abnormalities.(1) Many demographic and environmental factors are considered risk factors for the condition like: sex, age, BMI, social status and life style(2). IBS outspreaded all over the world varying between 14.7% to 16.5% in east Asian countries(3,4). As IBS is diagnosed mainly clinically, many scales have been developed to provide the best sensitivity for diagnosing the condition. The recent common criteria for diagnosing are ROME III and ROME VI. A meta-analysis conducted by Oka et al the pooled prevalence of IBS in 53 surveys that used the Rome III criteria from 38 countries was 9.2% (95% CI 7.6-10.8; I2 = 99.7%). Contrary, the pooled IBS prevalence among the 6 surveys that used the Rome IV criteria from 34 countries was 3.8% (95% CI 3.1-4.5; I2 = 96.6%)(5). The different prevalence rates are probably justified by the multifactorial nature of the disease and the various social status and environments from a country to another. However, there wasn't enough studies could define the prevalence of IBS among middle-eastern countries. The prevalence of IBS varies depending on socioeconomic factors, sex, and age. University students in the Middle East and North Africa are affected by many Lifestyle factors that participate in IBS by one way or another such as unhealthy eating habits (junk or fast food), cigarette smoking, physical inactivity and the fact that they're living low-income countries. IBS has also been associated with psychological factors such as stress, depression, and anxiety. Additionally, as their young age genetic factors and positive family history are implicated. Medical students, are more likely exposed to IBS risk factors as they have limited access to healthy meals, financial constraints, and a excessive exposure to stress secondary to their exceedingly demanding education and frequent examinations. Thus, they are more probably to develop IBS than other population subgroups.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Describe the prevalence of IBS among medical students

    assess the prevalence of IBS among medical students in the Middle East and North Africa and to investigate the sociodemographic,

    Page 3 of

    lifestyle, and clinical factors associated with IBS. A better understanding of IBS correlates is expected to improve our therapeutic approach to IBS in this population.

    Measured: 6 month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Oct 2023
  2. Study start20 Oct 2023 (estimated)
  3. Primary completion10 Mar 2024 (estimated)
  4. Study completion10 Oct 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Cross-sectional
Enrolment
1,131 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06097598
Sponsor's protocol ID
Irritable
Acronym
Irritablebowel
Status last verified
Oct 2023
First submitted
19 Oct 2023
Last updated
24 Oct 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Camilleri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med. 2012 Oct 25;367(17):1626-35. doi: 10.1056/NEJMra1207068. No abstract available.

    PubMed 23094724
  • Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol. 2020 Aug;17(8):473-486. doi: 10.1038/s41575-020-0286-8. Epub 2020 Apr 15.

    PubMed 32296140
  • Seger S, Nasharuddin NNB, Fernandez SL, Yunus SRBM, Shun NTM, Agarwal P, Burud I. Prevalence and factors associated with irritable bowel syndrome among medical students in a Malaysian private university: a cross sectional study. Pan Afr Med J. 2020 Oct 13;37:151. doi: 10.11604/pamj.2020.37.151.21716. eCollection 2020.

    PubMed 33425184
  • Basandra S, Bajaj D. Epidemiology of Dyspepsia and Irritable Bowel Syndrome (IBS) in Medical Students of Northern India. J Clin Diagn Res. 2014 Dec;8(12):JC13-6. doi: 10.7860/JCDR/2014/10710.5318. Epub 2014 Dec 5.

    PubMed 25653974
  • Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020 Oct;5(10):908-917. doi: 10.1016/S2468-1253(20)30217-X. Epub 2020 Jul 20.

    PubMed 32702295

Questions about this trial

What is this clinical trial studying?

An observational study of Faculty of Medicine, run by Assiut University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 24 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Describe the prevalence of IBS among medical students (time frame: 6 month). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06097598, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Oct 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in